Comparative assessment of disease burden in refractory and nonrefractory myasthenia gravis

Lire cet article en français

Takeaway

  • Quality of life (QoL) and disease burden is worse in people with refractory myasthenia gravis (MG) compared with nonrefractory MG.

Why this matters

  • Individuals with treatment-refractory MG have higher disease activity and increased exacerbations and hospitalizations than those with nonrefractory disease, highlighting the need for new therapeutic options.

Vous souhaitez en lire plus ?

Vous souhaitez en lire plus ?

Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.

Vous avez déjà un compte ? S'identifier

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.